GreenLight Biosciences, Samsung Biologics collaborate on COVID-19 mRNA vaccine manufacturing

By The Science Advisory Board staff writers

Samsung Biologics will collaborate with GreenLight Biologics to manufacture an mRNA COVID-19 vaccine candidate at a commercial scale. The partnership aims to accelerate production of GreenLight's COVID-19 vaccine candidate for phase III clinical trials, subject to regulatory approval.

The collaboration with Samsung will leverage GreenLight's existing manufacturing process, and technology transfer to Samsung will begin immediately, according to both firms.

GreenLight Biosciences is a biotechnology company that was founded in 2008; it is dedicated to making RNA products affordable and accessible. In August 2021, GreenLight announced plans to become publicly listed through a business combination with Environmental Impact Acquisition Corp.

Samsung Biologics is a contract manufacturing organization that provides integrated end-to-end contract development and manufacturing services.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking